Valuation : Shield Therapeutics plc

Market Cap 65.26M 88.49M 76.25M 71.5M 123M 8.46B 123M 848M 331M 4.27B 332M 325M 14.16B P/E 2026 *
436x
P/E 2027 * 8.22x
Enterprise Value 83.72M 114M 97.81M 91.71M 158M 10.85B 158M 1.09B 425M 5.48B 426M 417M 18.16B EV / Sales 2026 *
1.57x
EV / Sales 2027 * 1.19x
Free-Float
38.25%
Yield 2026 *
-
Yield 2027 * -
1 day+10.91%
1 week+25.77%
Current month+54.43%
1 month+38.64%
3 months+2.52%
6 months-37.44%
Current year-38.07%
1 week 4.7
Extreme 4.7
6.36
1 month 3.7
Extreme 3.7
6.36
Current year 3.7
Extreme 3.7
12.5
1 year 3.7
Extreme 3.7
12.5
3 years 1.06
Extreme 1.0625
12.85
5 years 1.06
Extreme 1.0625
52
10 years 1.06
Extreme 1.0625
202
Manager TitleAgeSince
Chief Executive Officer 64 23/07/2024
Investor Relations Contact - -
General Counsel - 31/12/2025
Director TitleAgeSince
Director/Board Member 68 31/01/2016
Chairman 70 17/06/2020
Director/Board Member 59 25/06/2020
Date Insider Type Main position Quantity % Market Cap.
14/10/25 Free

Chief Executive Officer

1,547,262 0.1485%
13/02/25 Free

Chief Executive Officer

5,000,000 0.4800%
13/02/25 Buy

Chief Executive Officer

575,000 0.0552%
Change 5-day change 1-year change 3-year change Capi.($)
+10.91%+25.77%-12.86%-40.49% 88.49M
-1.67%-4.78%+36.76%-4.88% 79.3B
-0.12%+1.56%-18.32%-37.21% 59.21B
-3.35%-4.92%+472.81%+18.32% 55.09B
-6.78%-4.19%-3.45%+28.01% 49.86B
-2.43%-2.35%+8.33%+163.57% 47.9B
-1.35%+0.79%+65.25%-18.22% 32.28B
-2.64%-2.69%+46.99%+90.61% 25.21B
-0.09%+4.98%+11.00%+199.03% 23.87B
-0.34%+1.35%+62.33%+125.87% 16.89B
Average -0.81%+1.50%+66.88%+52.46% 38.97B
Weighted average by Cap. -2.33%-2.04%+83.94%+41.62%

Financials

2026 *2027 *
Net sales 53.48M 72.52M 62.49M 58.59M 101M 6.93B 101M 695M 271M 3.5B 272M 266M 11.6B 69.92M 94.8M 81.69M 76.59M 132M 9.06B 132M 909M 355M 4.57B 356M 348M 15.17B
Net income 294K 399K 344K 322K 554K 38.1M 556K 3.82M 1.49M 19.23M 1.5M 1.46M 63.77M -147K -199K -172K -161K -277K -19.05M -278K -1.91M -745K -9.62M -748K -732K -31.89M
Net Debt 18.45M 25.02M 21.56M 20.21M 34.76M 2.39B 34.87M 240M 93.57M 1.21B 93.94M 91.89M 4B 18M 24.4M 21.03M 19.72M 33.9M 2.33B 34.01M 234M 91.26M 1.18B 91.62M 89.63M 3.9B
Logo Shield Therapeutics plc
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
Employees
61
Date Price Change Volume
28/08/26 GBX 6.100 +10.91% 12,625,633
27/08/26 GBX 5.500 +11.11% 2,571,043
26/08/26 GBX 4.950 +2.06% 2,773,251
25/08/26 GBX 4.850 +3.19% 715,214
24/08/26 GBX 4.700 -3.09% 1,429,474
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0610GBP
Average target price
0.1667GBP
Spread / Average Target
+173.23%

Annual profits - Rate of surprise